Lucia Cesarini
Overview
Explore the profile of Lucia Cesarini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cesarini L, Grignaffini F, Alisi A, Pastore A
Antioxidants (Basel)
. 2025 Jan;
13(12.
PMID: 39765791
Low molecular weight (LMW) thiols, particularly glutathione, play pathogenic roles in various multiorgan diseases. The liver is central for the production and systemic distribution of LMW thiols; thus, it is...
2.
Amanatidou A, Mikropoulou E, Amerikanou C, Milanovic M, Stojanoski S, Bjelan M, et al.
Metabolites
. 2023 Aug;
13(8).
PMID: 37623902
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) have been linked to changes in amino acid (AA) levels. The objective of the current study was to examine the relationship...
3.
Iavarone M, Invernizzi F, Ivanics T, Mazza S, Zavaglia C, Sanduzzi-Zamparelli M, et al.
Liver Transpl
. 2021 Aug;
27(12):1767-1778.
PMID: 34388851
Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best supportive care...
4.
Kanoni S, Kumar S, Amerikanou C, Kurth M, Stathopoulou M, Bourgeois S, et al.
Front Immunol
. 2021 May;
12:683028.
PMID: 34025683
Clinical Trial Registration: ClinicalTrials.gov, identifier NCT03135873.
5.
Amerikanou C, Kanoni S, Kaliora A, Barone A, Bjelan M, DAuria G, et al.
Mol Nutr Food Res
. 2021 Feb;
65(10):e2001178.
PMID: 33629536
Scope: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease with poor therapeutic strategies. Mastiha possesses antioxidant/anti-inflammatory and lipid-lowering properties. The authors investigate the effectiveness of Mastiha as...
6.
Grasselli C, Barbati A, Cesarini L, Pellegrino R, Di Renzo G
Clin Biochem
. 2020 Oct;
87:52-59.
PMID: 33068572
Introduction: The quantitative determination of urinary Cystatin C (cyst-C) associated with the qualitative analysis of its polymorphisms is an excellent method for early identification of newborns predisposed to renal function...
7.
Invernizzi F, Iavarone M, Zavaglia C, Mazza S, Maggi U, Cesarini L, et al.
Transplantation
. 2019 Sep;
104(3):568-574.
PMID: 31517781
Background: Sorafenib (SOR) is currently used for hepatocellular carcinoma (HCC) recurring after liver transplantation (LT) when HCC is unsuitable for surgical/locoregional treatments. We evaluated safety and effectiveness of early introduction...
8.
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
Caraceni P, Riggio O, Angeli P, Alessandria C, Neri S, Foschi F, et al.
Lancet
. 2018 Jun;
391(10138):2417-2429.
PMID: 29861076
Background: Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic...
9.
Cruciani G, Milani N, Benedetti P, Lepri S, Cesarini L, Baroni M, et al.
J Med Chem
. 2017 Dec;
61(1):360-371.
PMID: 29240409
Aldehyde oxidase (AOX) is a molibdo-flavoenzyme that has raised great interest in recent years, since its contribution in xenobiotic metabolism has not always been identified before clinical trials, with consequent...
10.
Zavaglia C, Okolicsanyi S, Cesarini L, Mazzarelli C, Pontecorvi V, Ciaccio A, et al.
J Hepatol
. 2016 Sep;
66(1):236-237.
PMID: 27592303
No abstract available.